文献速递消化系统肿瘤

比较四种一线双药方案治疗亚洲转移性胃癌患者的随机II期试验

Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
PubMed 文献 · Eur J Cancer · 2019-03-19

该随机II期研究纳入179例韩国复发/转移性胃癌初治患者,比较SP、FOLFOX、DF和PF四种双药方案;SP组中位PFS为8.4个月,优于其他方案(P=0.023),但四组OS无显著差异(P=0.143),所有方案耐受良好。

要点

  • SP组中位PFS为8.4个月,优于FOLFOX的5.8个月、DF的5.7个月和PF的4.2个月(P=0.023)。
  • 四组中位OS分别为SP 14.7个月、FOLFOX 11.3个月、DF 11.7个月、PF 10.8个月,无显著差异(P=0.143)。
  • 含铂组PFS有长于含紫杉烷组的趋势(7.2 vs 4.9个月,P=0.058),OS无显著差异。

核心结论

  • SP方案在PFS上显示最有利的结果,但四种方案间未观察到OS的显著差异。

研究设计与样本

  • 随机II期研究,纳入179例无既往化疗史的复发/转移性胃癌韩国患者,从2010年3月至2015年5月入组,因入组缓慢提前终止。
  • 患者被均匀随机分配至SP、FOLFOX、DF或PF四种双药方案,主要终点为无进展生存期(PFS),次要终点为总生存期(OS)、缓解率(RR)和安全性。

主要发现

  • 中位PFS:SP组8.4个月,FOLFOX组5.8个月,DF组5.7个月,PF组4.2个月(P=0.023)。
  • 中位OS:SP组14.7个月,FOLFOX组11.3个月,DF组11.7个月,PF组10.8个月(P=0.143)。
  • 缓解率:SP组18%,FOLFOX组23%,DF组16%,PF组32%。
  • 含铂组与含紫杉烷组PFS趋势:7.2 vs 4.9个月(P=0.058),OS无显著差异。
  • 105例患者在整个治疗过程中暴露于全部三种药物(铂类、紫杉烷和氟嘧啶),以铂类或紫杉烷起始的OS相同(13.3 vs 13.3个月,P=0.997)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因入组缓慢而提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Consensus has not been reached regarding the standard regimen for front-line chemotherapy of recurrent/metastatic gastric cancer. In this randomised phase II study, we compared four doublet regimens: S-1 and cisplatin (SP); oxaliplatin and 5-FU (FOLFOX); docetaxel and 5-FU (DF) and paclitaxel and 5-FU (PF). PATIENTS AND METHODS: Patients without prior history of chemotherapy for recurrent/metastatic gastric cancer were randomised evenly to each regimen. The primary end-point was progression-free survival (PFS). The secondary end-points were overall survival (OS), response rate (RR) and safety profile. RESULTS: A total of 179 Korean patients were enrolled from March 2010 to May 2015. The study was prematurely terminated because of slow accrual. At data cut-off, the median PFS was 8.4 months for SP, 5.8 months for FOLFOX, 5.7 months for DF and 4.2 months for PF (P = 0.023). The median OS was 14.7 months for SP, 11.3 months for FOLFOX, 11.7 months for DF and 10.8 months for PF (P = 0.143). RR was 18%, 23%, 16% and 32% for SP, FOLFOX, DF and PF, respectively. The platinum group displayed a longer PFS trend than the taxane group (7.2 versus 4.9 months, P = 0.058), but no significant difference in OS was found. Notably, 105 patients were exposed to all three drugs (platinum, taxane and fluoropyrimidine) throughout the treatment course, and OS was identical whether starting with platinum or taxane (13.3 versus 13.3 months, P = 0.997). All regimens were well tolerated. CONCLUSION: SP showed the most favourable results in PFS, whereas a significant difference in OS was not observed among the four regimens.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kim C, Chon HJ, Kim JH, et al. Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. Eur J Cancer. 2019. PMID: 30901609. doi:10.1016/j.ejca.2018.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。